Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Yuankai Shi

44PUBLICATIONS
43CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

Sort by Publication Date:
|Jun 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

|Jun 12, 2026
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

|Apr 02, 2026
Rezivertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study.

Sheng Yang, Yanqiu Zhao, Meili Sun

|Feb 15, 2026
DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Guangyu Fan, Le Tang, Tongji Xie

|Aug 25, 2025
Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid-Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non-Small Cell Lung Cancer.

Ruyun Gao, Ning Lou, Sheng Yang

|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

Huiyang Shi, Miaohan Wang, Junling Li

Pageof 8

Frequent Collaborators

6 joint publications

Xiaohong Han

3 joint publications

Haohua Zhu

3 joint publications

Le Tang

3 joint publications

Jiarui Yao

3 joint publications

Ning Lou

3 joint publications

Rongrong Luo

2 joint publications

Yu Jiang

2 joint publications

Yu Feng

2 joint publications

Xingsheng Hu

2 joint publications

Yunxia Tao

Frequent Collaborators

6 joint publications

Xiaohong Han

3 joint publications

Haohua Zhu

3 joint publications

Le Tang

3 joint publications

Jiarui Yao